No Data
No Data
AbbVie Invests in Sionna as Part of Licensing Deal for CF Drugs
Express News | Sionna Therapeutics Secures Exclusive Worldwide Rights To Develop And Commercialize AbbVie's CF Compounds ABBV-2222
Express News | Sionna Therapeutics: Abbvie to Get Upfront Payment, Equity Investment in Sionna
Express News | Sionna Therapeutics Expands Pipeline With Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement With Abbvie
SKYRIZI's Approval For Ulcerative Colitis Treatment Expands AbbVie's Portfolio Across Immune-mediated Inflammatory Diseases | DelveInsight
Ulcerative colitis is an idiopathic inflammatory bowel disease affecting ~1.5 million patients in the US and with an unknown exact cause. It affects...
AbbVie Looks to Add an Eighth Indication for JAK Inhibitor Rinvoq